Display Settings:

Format

Send to:

Choose Destination
    Depress Anxiety. 2000;12(2):111-3.

    Bupropion-SR in treatment of social phobia.

    Source

    Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425, USA. emmanunp@musc.edu

    Abstract

    A 12-week, open label flexible dosing study was conducted to evaluate the efficacy of bupropion-SR in the treatment of generalized social phobia. The primary outcome measures include the Clinical Global Impression of Improvement (CGI-I) and the Brief Social Phobia Rating Scale (BSPS). A total of 18 subjects were enrolled. Five of the ten subjects who completed all 12 weeks were considered as responders. Response to treatment was defined as a CGI-I score of 1 or 2, ("much improved" or "very much improved," respectively) and a > 50% decrease in BSPS score. The final doses for the completers ranged between 200 and 400 mg/day (mean 366 +/- 68 mg/day). The medication was generally well tolerated. Findings from this open-label trial suggest that bupropion-SR may be useful in treating generalized social phobia.

    PMID:
    11091936
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Chemical compound information

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk